Verrica Pharmaceuticals (VRCA) Cash from Investing Activities (2018 - 2024)
Verrica Pharmaceuticals (VRCA) posted quarterly Cash from Investing Activities of $8000.0 for Q4 2024, up 103.52% year-over-year from $3930.7 in Q1 2024, and up 150.0% quarter-over-quarter from -$16000.0 in Q3 2024.
Verrica Pharmaceuticals (VRCA) Cash from Investing Activities (2018 - 2024) Analysis & Trends
Verrica Pharmaceuticals' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at $8000.0 for Q4 2024.
- In Q4 2024, Cash from Investing Activities rose 103.52% year-over-year to $8000.0; the TTM figure through Sep 2025 stood at $8000.0 (up 103.15% YoY), while the FY2024 annual figure was -$19000.0, up 94.75% from the prior year.
- Cash from Investing Activities for Q4 2024 stood at $8000.0, up from -$16000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $43.0 million in Q1 2022, with the low at -$24.1 million in Q3 2020.
- The 5-year median for Cash from Investing Activities is $8000.0 (2024), against an average of $2.6 million.
- Peak annual rise in Cash from Investing Activities reached 1090.11% in 2020, while the deepest fall reached 1089.64% in 2020.
- Verrica Pharmaceuticals' Cash from Investing Activities stood at -$858000.0 in 2020, then jumped by 567.48% to $4.0 million in 2021, then surged by 68.39% to $6.8 million in 2022, then tumbled by 103.36% to -$227000.0 in 2023, then soared by 103.52% to $8000.0 in 2024.
- Business Quant data shows VRCA's Cash from Investing Activities at $8000.0 in Q4 2024, -$16000.0 in Q3 2024, and -$11000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 8,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | -16,000.00 |
| Sep 30, 2024 | -16,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Jun 30, 2024 | -11,000.00 |
| Dec 31, 2023 | -227,000.00 |
| Dec 31, 2023 | -227,000.00 |
| Sep 30, 2023 | -65,000.00 |
| Sep 30, 2023 | -65,000.00 |
| Jun 30, 2023 | -59,000.00 |
| Jun 30, 2023 | -59,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Mar 31, 2023 | -11,000.00 |
| Dec 31, 2022 | 6.75 Mn |
| Dec 31, 2022 | 6.75 Mn |
| Sep 30, 2022 | 2.07 Mn |
| Sep 30, 2022 | 2.07 Mn |
| Jun 30, 2022 | 2.21 Mn |
| Jun 30, 2022 | 2.21 Mn |